中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Influencing factors for recompensation in patients with decompensated hepatitis C cirrhosis

DOI: 10.12449/JCH250212
Research funding:

YouAn Specialist Alliance Research Fund (LM202014)

More Information
  • Corresponding author: LIU Li, liuli197210@163.com (ORCID: 0000-0001-7712-4931)
  • Received Date: 2024-05-29
  • Accepted Date: 2024-06-18
  • Published Date: 2025-02-25
  •   Objective  To investigate the influencing factors for recompensation in patients with decompensated hepatitis C cirrhosis, and to establish a predictive model.  Methods  A total of 217 patients who were diagnosed with decompensated hepatitis C cirrhosis and were admitted to The Third People’s Hospital of Kunming l from January, 2019 to December, 2022 were enrolled, among whom 63 patients who were readmitted within at least 1 year and had no portal hypertension-related complications were enrolled as recompensation group, and 154 patients without recompensation were enrolled as control group. Related clinical data were collected, and univariate and multivariate analyses were performed for the factors that may affect the occurrence of recompensation. The independent-samples t test was used for comparison of normally distributed measurement data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed measurement data between two groups; the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups. A binary Logistic regression analysis was used to investigate the influencing factors for recompensation in patients with decompensated hepatitis C cirrhosis, and the receiver operating characteristic (ROC) curve was used to assess the predictive performance of the model.  Results  Among the 217 patients with decompensated hepatitis C cirrhosis, 63 (29.03%) had recompensation. There were significant differences between the recompensation group and the control group in HIV history (χ2=4.566, P=0.034), history of partial splenic embolism (χ2=6.687, P=0.014), Child-Pugh classification (χ2=11.978, P=0.003), grade of ascites (χ2=14.229, P<0.001), albumin (t=4.063, P<0.001), prealbumin (Z=-3.077, P=0.002), high-density lipoprotein (t=2.854, P=0.011), high-sensitivity C-reactive protein (Z=-2.447, P=0.014), prothrombin time (Z=-2.441, P=0.015), carcinoembryonic antigen (Z=-2.113, P=0.035), alpha-fetoprotein (AFP) (Z=-2.063, P=0.039), CA125 (Z=-2.270, P=0.023), TT3 (Z=-3.304, P<0.001), TT4 (Z=-2.221, P=0.026), CD45+Z=-2.278, P=0.023), interleukin-5 (Z=-2.845, P=0.004), tumor necrosis factor-α (Z=-2.176, P=0.030), and portal vein width (Z=-5.283, P=0.005). The multivariate analysis showed that history of partial splenic embolism (odds ratio [OR]=3.064, P=0.049), HIV history (OR=0.195, P=0.027), a small amount of ascites (OR=3.390, P=0.017), AFP (OR=1.003, P=0.004), and portal vein width (OR=0.600, P<0.001) were independent influencing factors for the occurrence of recompensation in patients with decompensated hepatitis C cirrhosis. The ROC curve analysis showed that HIV history, grade of ascites, history of partial splenic embolism, AFP, portal vein width, and the combined predictive model of these indices had an area under the ROC curve of 0.556, 0.641, 0.560, 0.589, 0.745, and 0.817, respectively.  Conclusion  For patients with decompensated hepatitis C cirrhosis, those with a history of partial splenic embolism, a small amount of ascites, and an increase in AFP level are more likely to experience recompensation, while those with a history of HIV and an increase in portal vein width are less likely to experience recompensation.

     

  • [1]
    World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016-2021: actions for impact[M]. Geneva: World Health Organization, 2021.
    [2]
    COLLABORATORS POH. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study[J]. Lancet Gastroenterol Hepatol, 2022, 7( 5): 396- 415. DOI: 10.1016/S2468-1253(21)00472-6.
    [3]
    JALAN R, D’AMICO G, TREBICKA J, et al. New clinical and pathophysiological perspectives defining the trajectory of cirrhosis[J]. J Hepatol, 2021, 75( Suppl 1): S14- S26. DOI: 10.1016/j.jhep.2021.01.018.
    [4]
    YEO YH, HE XY, LV F, et al. Trends of cirrhosis-related mortality in the USA during the COVID-19 pandemic[J]. J Clin Transl Hepatol, 2023, 11( 3): 751- 756. DOI: 10.14218/JCTH.2022.00313.
    [5]
    CRAIG AJ, von FELDEN J, GARCIA-LEZANA T, et al. Tumour evolution in hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2020, 17( 3): 139- 152. DOI: 10.1038/s41575-019-0229-4.
    [6]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33( 10): 1847- 1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.

    中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33( 10): 1847- 1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
    [7]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VII-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
    [8]
    Hepatology Branch of Chinese Medical Association. Guidelines on the management of ascites in cirrhosis(2023 version)[J]. Chin J Hepatol, 2023, 31( 8): 813- 826. DOI: 10.3760/cma.j.cn501113-20230719-00011.

    中华医学会肝病学分会. 肝硬化腹水诊疗指南(2023年版)[J]. 中华肝脏病杂志, 2023, 31( 8): 813- 826. DOI: 10.3760/cma.j.cn501113-20230719-00011.
    [9]
    KIM TH, UM SH, LEE YS, et al. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy[J]. Aliment Pharmacol Ther, 2022, 55( 1): 83- 96. DOI: 10.1111/apt.16658.
    [10]
    JANG JW, CHOI JY, KIM YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis[J]. Hepatology, 2015, 61( 6): 1809- 1820. DOI: 10.1002/hep.27723.
    [11]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Clin Infect Dis, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15( 6): 428- 447. DOl: 10.3760/cma.j.issn.1674-2397.2022.06.002. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002
    [12]
    Chinese Society of Hepatology, Chinese Society of Gastroenterology, Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2023, 9( 3): 527- 538. DOI: 10.3760/cmaj.cn501113-20220824-00436.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2023, 39( 3): 527- 538. DOI: 10.3760/cmaj.cn501113-20220824-00436.
    [13]
    General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOl: 10.3969/j.issn.1001-5256.2022.02.009. DOI: 10.3969/j.issn.1001-5256.2022.02.009
    [14]
    WANG Q, ZHAO H, DENG Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77( 6): 1564- 1572. DOI: 10.1016/j.jhep.2022.07.037.
    [15]
    ZHANG T, DENG Y, KANG HY, et al. Recompensation of complications in patients with hepatitis B virus-related decompensated cirrhosis treated with entecavir antiviral therapy[J]. Chin J Hepatol, 2023, 31( 7): 692- 697. DOI: 10.3760/cma.j.cn501113-20230324-00126.

    张婷, 邓优, 康海燕, 等. 恩替卡韦抗病毒治疗的乙型肝炎失代偿期肝硬化患者并发症的再代偿[J]. 中华肝脏病杂志, 2023, 31( 7): 692- 697. DOI: 10.3760/cma.j.cn501113-20230324-00126.
    [16]
    HOFER BS, SIMBRUNNER B, HARTL L, et al. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis[J]. Liver Int, 2023, 43( 10): 2220- 2231. DOI: 10.1111/liv.15676.
    [17]
    HOFER BS, BURGHART L, HALILBASIC E, et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis[J]. Aliment Pharmacol Ther, 2024, 59( 8): 962- 972. DOI: 10.1111/apt.17908.
    [18]
    BENMASSAOUD A, FREEMAN SC, ROCCARINA D, et al. Treatment for ascites in adults with decompensated liver cirrhosis: A network meta-analysis[J]. Cochrane Database Syst Rev, 2020, 1( 1): CD013123. DOI: 10.1002/14651858.CD013123.pub2.
    [19]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69( 2): 406- 460. DOI: 10.1016/j.jhep.2018.03.024.
    [20]
    RIPOLL C, GROSZMANN R, GARCIA-TSAO G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J]. Gastroenterology, 2007, 133( 2): 481- 488. DOI: 10.1053/j.gastro.2007.05.024.
    [21]
    CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis(ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391( 10138): 2417- 2429. DOI: 10.1016/S0140-6736(18)30840-7.
    [22]
    POSE E, TORRENTS A, REVERTER E, et al. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement[J]. J Hepatol, 2021, 75( 2): 275- 283. DOI: 10.1016/j.jhep.2021.02.033.
    [23]
    ARAVINTHAN AD, BARBAS AS, DOYLE AC, et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: A case-control study[J]. Transpl Int, 2017, 30( 11): 1140- 1149. DOI: 10.1111/tri.13008.
    [24]
    GIARD JM, DODGE JL, TERRAULT NA. Superior wait-list outcomes in patients with alcohol-associated liver disease compared with other indications for liver transplantation[J]. Liver Transpl, 2019, 25( 9): 1310- 1320. DOI: 10.1002/lt.25485.
    [25]
    JACHS M, HARTL L, SCHAUFLER D, et al. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes[J]. Gut, 2021, 70( 9): 1758- 1767. DOI: 10.1136/gutjnl-2020-322712.
    [26]
    REIBERGER T, FERLITSCH A, PAYER BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis[J]. J Hepatol, 2013, 58( 5): 911- 921. DOI: 10.1016/j.jhep.2012.12.011.
    [27]
    GLUUD LL, KRAG A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults[J]. Cochrane Database Syst Rev, 2012( 8): CD004544. DOI: 10.1002/14651858.CD004544.pub2.
    [28]
    HERNÁNDEZ-GEA V, ARACIL C, COLOMO A, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers[J]. Am J Gastroenterol, 2012, 107( 3): 418- 427. DOI: 10.1038/ajg.2011.456.
    [29]
    D’AMICO G, MORABITO A, D’AMICO M, et al. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis[J]. Hepatol Int, 2018, 12( Suppl 1): 34- 43. DOI: 10.1007/s12072-017-9808-z.
    [30]
    XIE QY, GAO FW, LEI ZH, et al. Comparative study of non-selective and highly selective splenic artery embolization in patients with liver cirrhosis secondary to hypersplenism[J]. Chin J Hepatobiliary Surgery, 2021, 27( 12): 917- 922. DOI: 10.3760/cma.j.cn113884-20210527-00182.

    谢青云, 高峰畏, 雷泽华, 等. 脾动脉非选择性与高选择性插管后部分脾栓塞术在肝硬化继发脾功能亢进患者中的对比研究[J]. 中华肝胆外科杂志, 2021, 27( 12): 917- 922. DOI: 10.3760/cma.j.cn113884-20210527-00182.
    [31]
    LI ZW, WANG YQ, ZHANG YW. The mechanism of action of partial splenic artery embolization in treatment of liver cirrhosis and hypersplenism[J]. J Clin Hepatol, 2023, 39( 7): 1714- 1720. DOI: 10.3969/j.issn.1001-5256.2023.07.029.

    李宗伟, 汪桠琴, 张跃伟. 部分脾动脉栓塞治疗肝硬化脾功能亢进的作用机制[J]. 临床肝胆病杂志, 2023, 39( 7): 1714- 1720. DOI: 10.3969/j.issn.1001-5256.2023.07.029.
    [32]
    MADOFF DC, DENYS A, WALLACE MJ, et al. Splenic arterial interventions: Anatomy, indications, technical considerations, and potential complications[J]. Radiographics, 2005, 25( Suppl 1): S191- S211. DOI: 10.1148/rg.25si055504.
    [33]
    BAI L, LI QG. Effect of partial splenic embolization on inflammatory response and coagulation in patients with hypersplenism in liver cirrhosis[J]. Clin Res, 2023, 31( 8): 36- 38. DOI: 10.12385/j.issn.2096-1278(2023)08-0036-03.

    白露, 李庆刚. 部分脾栓塞术对肝硬化脾功能亢进患者炎症反应及凝血功能的影响[J]. 临床研究, 2023, 31( 8): 36- 38. DOI: 10.12385/j.issn.2096-1278(2023)08-0036-03.
    [34]
    PAVEL V, SCHARF G, MESTER P, et al. Partial splenic embolization as a rescue and emergency treatment for portal hypertension and gastroesophageal variceal hemorrhage[J]. BMC Gastroenterol, 2023, 23( 1): 180. DOI: 10.1186/s12876-023-02808-1.
    [35]
    ISHIKAWA T, SASAKI R, NISHIMURA T, et al. A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification[J]. PLoS One, 2019, 14( 9): e0223153. DOI: 10.1371/journal.pone.0223153.
    [36]
    Committee on HIV/Liver Diseases, Chinese Association of STD and AIDS Prevention and Control; Guangzhou Eighth People’s Hospital, Guangzhou Medical University. Chinese expert consensus on the diagnosis and treatment of HIV co-infection with HBV and HCV[J]. J Clin Hepatol, 2024, 40( 6): 1107- 1113. DOI: 10.12449/JCH240607.

    中国性病艾滋病防治协会HIV合并肝病专业委员会, 广州医科大学附属市八医院. 中国HIV合并HBV、HCV感染诊治专家共识[J]. 临床肝胆病杂志, 2024, 40( 6): 1107- 1113. DOI: 10.12449/JCH240607.
    [37]
    van den EYNDE E, CRESPO M, ESTEBAN JI, et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: A pilot trial[J]. Clin Infect Dis, 2009, 48( 8): 1152- 1159. DOI: 10.1086/597470.
    [38]
    PINEDA JA, GARCÍA-GARCÍA JA, AGUILAR-GUISADO M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy[J]. Hepatology, 2007, 46( 3): 622- 630. DOI: 10.1002/hep.21757.
    [39]
    WEN J, ZHOU Y, WANG J, et al. Interactions between Th1 cells and Tregs affect regulation of hepatic fibrosis in biliary atresia through the IFN-γ/STAT1 pathway[J]. Cell Death Differ, 2017, 24( 6): 997- 1006. DOI: 10.1038/cdd.2017.31.
    [40]
    DAGUR RS, WANG WM, CHENG Y, et al. Human hepatocyte depletion in the presence of HIV-1 infection in dual reconstituted humanized mice[J]. Biol Open, 2018, 7( 2): bio029785. DOI: 10.1242/bio.029785.
    [41]
    ARIFIN KT, SULAIMAN S, SAAD SM, et al. Elevation oftumour markers TGF-β,M2-PK, OV-6 and AFP in hepatocellular carcinoma(HCC)-induced rats and their suppression bymicroalgae Chlorella vulgaris[J]. BMC Cancer, 2017, 17( 1): 879. DOI: 10.1186/s12885-017-3883-3.
    [42]
    MASETTI C, LIONETTI R, LUPO M, et al. Lack of reduction in serumalpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis[J]. J Viral Hepat, 2018, 25( 12): 1493- 1500. DOI: 10.1111/jvh.12982.
    [43]
    ZHAO P, ZHAI YF, ZHANG HH. Application of serum alpha fetoprotein and prothrombin time activity in predicting prognosis of patients with acute-on-chronic liver failure[J]. J Prac Hepat, 2017, 20( 2): 230- 231. DOI: 10.3969/j.issn.1672-5069.2017.02.027.

    赵萍, 翟玉峰, 张怀宏. 血清甲胎蛋白和凝血酶原活动度水平对慢加急性肝衰竭患者预后的预测价值研究[J]. 实用肝脏病杂志, 2017, 20( 2): 230- 231. DOI: 10.3969/j.issn.1672-5069.2017.02.027.
    [44]
    ZHANG AM, YOU SL, WAN ZH, et al. Relation of liver fibrosis indicators and prognosis in hepatitis B-related acute on chronic liver failure[J]. J Clin Hepatol, 2012, 28( 6): 459- 461. DOI: 10.3969/j.issn.1001-5256.2012.06.016.

    张爱民, 游绍莉, 万志红, 等. 乙型肝炎病毒相关慢加急性肝衰竭患者肝纤维化、肝功能、病毒学指标及甲胎蛋白水平与预后的关系[J]. 临床肝胆病杂志, 2012, 28( 6): 459- 461. DOI: 10.3969/j.issn.1001-5256.2012.06.016.
  • Relative Articles

    [1]Wendi LIU, Peng WANG, Heping HU, Huabang ZHOU. ABCB4 gene mutation-associated liver cirrhosis with gallstones: A case report[J]. Journal of Clinical Hepatology, 2024, 40(3): 585-588. doi: 10.12449/JCH240324
    [2]Dan YANG, Cuiwei ZHANG, Mingming DENG. A compound heterozygous mutation in the ATP7B gene with acute fatty liver of pregnancy: A case report[J]. Journal of Clinical Hepatology, 2022, 38(1): 167-169. doi: 10.3969/j.issn.1001-5256.2022.01.027
    [3]Xianmei GAO, Xiaoxiao YU, Zhen YU, Linlin ZHANG, Jie YANG. Homozygous mutation in monozygotic twins in a family with hepatolenticular degeneration[J]. Journal of Clinical Hepatology, 2022, 38(9): 2120-2122. doi: 10.3969/j.issn.1001-5256.2022.09.032
    [4]Lei HUA, Quan SUN, Wenbin XU, Long ZHANG, Gongqiang WANG. ABCB4 gene mutation-associated liver cirrhosis misdiagnosed as Wilson's disease: A case report[J]. Journal of Clinical Hepatology, 2021, 37(6): 1419-1420. doi: 10.3969/j.issn.1001-5256.2021.06.039
    [5]Shuqin LI, Jing ZHOU, Yuan GAO, Xiaoyan MA, Liping WANG. Antiviral effect of entecavir in chronic hepatitis B patients with rtA181V/T mutation[J]. Journal of Clinical Hepatology, 2021, 37(5): 1053-1058. doi: 10.3969/j.issn.1001-5256.2021.05.016
    [6]Yong ZHANG, Zhengfa MAO. Association of tuberous sclerosis gene 1/2 mutations with the progression of hepatocellular carcinoma and prognosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 84-88. doi: 10.3969/j.issn.1001-5256.2021.01.017
    [7]Xu Shuai, Zhang LiPing. Research advances in the role of exosomes in non-neoplastic liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(4): 940-943. doi: 10.3969/j.issn.1001-5256.2020.04.052
    [8]Lin Jian, Fang XueQing, Song YouLiang. A case of recurrent liver dysfunction caused by NBAS gene mutation[J]. Journal of Clinical Hepatology, 2020, 36(9): 2069-2071. doi: 10.3969/j.issn.1001-5256.2020.09.034
    [9]Yang Fan, Wang YiRou, Yu XiaoDan, Ma Xiong, Wang XiuMin. Congenital hepatic fibrosis with retinitis pigmentosa caused by mutations of the TMEM67 gene and CNGB1 gene: A case report[J]. Journal of Clinical Hepatology, 2020, 36(7): 1593-1595. doi: 10.3969/j.issn.1001-5256.2020.07.029
    [10]Zheng YiShan. Early diagnosis of liver disease during pregnancy should be taken seriously[J]. Journal of Clinical Hepatology, 2019, 35(7): 1435-1438. doi: 10.3969/j.issn.1001-5256.2019.07.005
    [11]Liang Chen, Bai Li, Zheng SuJun. Research advances in mutation characteristics of the UGT1A1 gene in Gilbert syndrome and its influence on intrahepatic and extrahepatic systems[J]. Journal of Clinical Hepatology, 2019, 35(7): 1632-1635. doi: 10.3969/j.issn.1001-5256.2019.07.046
    [12]Li Ning, Zhang Xin, Li Rui, Jiao Lin. Hepatolenticular degeneration with MTHFR gene mutation: A case report[J]. Journal of Clinical Hepatology, 2019, 35(11): 2549-2550. doi: 10.3969/j.issn.1001-5256.2019.11.033
    [13]Zhou HuaBang, Hu HePing. Challenges in precise treatment for primary liver cancer based on gene mutation[J]. Journal of Clinical Hepatology, 2017, 33(7): 1209-1210. doi: 10.3969/j.issn.1001-5256.2017.07.001
    [14]Pang Ting, Xing HuiChun. Correlation between drug-resistance gene mutations and hepatocellular carcinoma in patients with hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2017, 33(1): 82-86. doi: 10.3969/j.issn.1001-5256.2017.01.017
    [15]Zhang XiaoTong, Guo LiPing. Value of ultrasonic elastography in diagnosis of liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(11): 2210-2213. doi: 10.3969/j.issn.1001-5256.2016.11.048
    [16]Chen Juan, Yin HuaBin. Main applications of diffusion-weighted magnetic resonance imaging in liver diseases[J]. Journal of Clinical Hepatology, 2015, 31(1): 139-142. doi: 10.3969/j.issn.1001-5256.2015.01.032
    [17]Guo HongMei, Zheng BiXia, Li Mei. Neonatal intrahepatic cholestasis caused by citrin deficiency due to SLC25A13 gene mutations: a clinical analysis of 21cases in Nanjing, China[J]. Journal of Clinical Hepatology, 2014, 30(11): 1127-1131. doi: 10.3969/j.issn.1001-5256.2014.11.008
    [18]Peng XiaoFang, Liu HaiYing. Research advances in circulating miRNAs for diagnosis of hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2014, 30(9): 965-968. doi: 10.3969/j.issn.1001-5256.2014.09.032
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(5)

    Article Metrics

    Article views (97) PDF downloads(16) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return